Gilead Sciences reports $7.8 billion revenue for quarter ended June 30, 2026, up 10.2%
Gilead Sciences reported revenue of $7.8 billion for the quarter ended June 30, 2026, an increase of 10.2% from the same quarter a year earlier ($7.08 billion).
For the same period it posted a net loss of $10.5 billion, or $-8.45 per diluted share (1.56 a year earlier).
That is a net margin of -134.5%.
On Sanad's AAOIFI Standard 21 screen, Gilead Sciences is currently compliant: interest-bearing debt is 12.4% of market capitalisation (limit 30%), and impure income is 1.2% of revenue (limit 5%).
Is Gilead Sciences halal?
See the full AAOIFI screening of Gilead Sciences
See the full AAOIFI screening of Gilead Sciences
Source: 10-Q filed with the U.S. Securities and Exchange Commission on August 6, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.